Etiopathogenesis and treatment of Parkinson's disease

Current Topics in Medicinal Chemistry

Volumn 9, Issue 10, 2009, Pages 860-868

  Gallagher, David A ^a   Schapira, Anthony H V ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Alpha synuclein; Lewy body; LRRK2; Mitochondria; Oxidative stress; Parkinson's disease; PINK1

Indexed keywords

ANGIOTENSIN II ANTAGONIST; ANTIHYPERTENSIVE AGENT; APOMORPHINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BROMOCRIPTINE MESILATE; CALCIUM ANTAGONIST; CALCIUM CHANNEL BLOCKING AGENT; CARBIDOPA PLUS LEVODOPA; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOPAMINE RECEPTOR STIMULATING AGENT; ENTACAPONE; GLUTAMATE RECEPTOR; LEVODOPA; NEUROTRANSMITTER; PIRIBEDIL; PLACEBO; PRAMIPEXOLE; RASAGILINE; ROPINIROLE; ROTIGOTINE; SELEGILINE; TOCOPHEROL; TOLCAPONE;

APOPTOSIS; ARTICLE; AUTOPHAGY; BIOENERGY; CELL CULTURE; CELL DEATH; CELL LOSS; CLINICAL TRIAL; DELUSION; DEPRESSION; DOPAMINERGIC NERVE CELL; DOPAMINERGIC SYSTEM; DRUG ACTIVITY; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG METABOLISM; DRUG RELEASE; DRUG RESPONSE; DRUG TOLERABILITY; DRUG UPTAKE; DYSKINESIA; EXCITOTOXICITY; FOLLOW UP; HALLUCINATION; HUMAN; INSOMNIA; MOTOR DEVELOPMENT; MOTOR DYSFUNCTION; MOTOR PERFORMANCE; NERVE DEGENERATION; NEUROIMAGING; NONHUMAN; OLIGODENDROGLIA; ORTHOSTATIC HYPOTENSION; OXIDATIVE STRESS; PARKINSON DISEASE; QUALITY OF LIFE; RATING SCALE; SCORING SYSTEM; SEASONAL VARIATION; SIDE EFFECT; SLEEP DISORDER; SOMNOLENCE; SUBSTANTIA NIGRA; TREATMENT OUTCOME;

ANIMALS; ANTIPARKINSON AGENTS; DOPAMINE; HUMANS; NEURONS; PARKINSON DISEASE;

EID: 74249119940     PISSN: 15680266     EISSN: None     Source Type: Journal    
DOI: 10.2174/156802609789378227     Document Type: Article

References (86)

1. Gasser, T. Update on the genetics of Parkinson's disease. Mov. Disord. 2007, 22 (Suppl. 17), S343-S350.
2. Mata, I. F.; Samii, A.; Schneer, S. H.; Roberts, J. W.; Griffith, A.; Leis, B. C.; Schellenberg, G. D.; Sidransky, E.; Bird, T. D.; Leverenz, J. B.; Tsuang, D.; Zabetian, C. P. Glucocerebrosidase gene mutations: a risk factor for Lewy body disorders. Arch. Neurol. 2008, 65, 379-382.
3. Schapira, A. H. Mitochondria in the aetiology and pathogenesis of parkinson's disease. Lancet Neurol. 2008, 7, 97-109.
4. Schapira, A. H. Mitochondrial dysfunction in Parkinson's disease. Cell Death Differ. 2007, 14, 1261-1266.
5. Schapira, A. H.; Olanow, C. W. Neuroprotection in Parkinson disease: mysteries, myths, and misconceptions. JAMA 2004, 291, 358-364.
6. Chaudhuri, K. R.; Healy, D. G.; Schapira, A. H. Non-motor symptoms of Parkinson's disease: Diagnosis and Management. Lancet Neurol. 2006, 5, 235-245.
7. Braak, H.; Del, T. K.; Bratzke, H.; Hamm-Clement, J.; Sandmann-Keil, D.; Rub, U. Staging of the intracerebral inclusion body pathology associated with idiopathic Parkinson's disease (preclinical and clinical stages). J. Neurol. 2002, 249 (Suppl. 3), III/1-III/5.
8. Chaudhuri K. R.; Schapira A. H. Non-motor symptoms of Parkinson's disease: dopaminergic pathophysiology and treatment. Lancet Neurol. 2009, 8, 464-474.
9. Klimek, V.; Schenck, J. E.; Han, H.; Stockmeier, C. A.; Ordway, G. A. Dopaminergic abnormalities in amygdaloid nuclei in major depression: a postmortem study. Biol. Psychiatry 2002, 52, 740-748.
10. Bruck, A.; Aalto, S.; Nurmi, E.; Bergman, J.; Rinne, J. O. Cortical 6-[18F]fluoro-L-dopa uptake and frontal cognitive functions in early Parkinson's disease. Neurobiol. Aging 2005, 26, 891-898.
11. Linazasoro, G. Pathophysiology of motor complications in Parkinson disease: postsynaptic mechanisms are crucial. Arch. Neurol. 2007, 64, 137-140.
12. Schapira, A. H.; Bezard, E.; Brotchie, J.; Calon, F.; Collingridge, G. L.; Ferger, B.; Hengerer, B.; Hirsch, E.; Jenner, P.; Le, N. N.; Obeso, J. A.; Schwarzschild, M. A.; Spampinato, U.; Davidai, G. Novel pharmacological targets for the treatment of Parkinson's disease. Nat. Rev. Drug Discov. 2006, 5, 845-854.
13. de la Fuente-Fernández R. Presynaptic mechanisms of motor complications in Parkinson disease. Arch. Neurol. 2007, 64, 141-143.
14. Olanow, W.; Schapira, A. H.; Rascol, O. Continuous dopamine-receptor stimulation in early Parkinson's disease. Trends Neurosci. 2000, 23, S117-S126.
15. Schapira, A. H. Disease modification in Parkinson's disease. Lancet Neurol. 2004, 3, 362-368.
16. Imamura, K.; Takeshima, T.; Nakaso, K.; Ito, S.; Nakashima, K. Pramipexole has astrocyte-mediated neuroprotective effects against lactacystin toxicity. Neurosci. Lett. 2008, 440, 97-102.
17. Du, F.; Li, R.; Huang, Y.; Li, X.; Le, W. Dopamine D3 receptor-preferring agonists induce neurotrophic effects on mesencephalic dopamine neurons. Eur. J. Neurosci. 2005, 22, 2422-2430.
18. Gu, M.; Iravani, M. M.; Cooper, J. M.; King, D.; Jenner, P.; Schapira, A. H. Pramipexole protects against apoptotic cell death by non-dopaminergic mechanisms. J. Neurochem. 2004, 91, 1075-1081.
19. Takata, K.; Kitamura, Y.; Kakimura, J.; Kohno, Y.; Taniguchi, T. Increase of bcl-2 protein in neuronal dendritic processes of cerebral cortex and hippocampus by the antiparkinsonian drugs, talipexole and pramipexole. Brain Res. 2000, 872, 236-241.
20. Fujita, Y.; Izawa, Y.; Ali, N.; Kanematsu, Y.; Tsuchiya, K.; Hamano, S.; Tamaki, T.; Yoshizumi, M. Pramipexole protects against H2O2-induced PC12 cell death. Naunyn Schmiedebergs Arch. Pharmacol. 2006, 372, 257-266.
21. Ferger, B.; Teismann, P.; Mierau, J. The dopamine agonist pramipexole scavenges hydroxyl free radicals induced by striatal application of 6-hydroxydopamine in rats: an in vivo microdialysis study. Brain Res. 2000, 883, 216-223.
22. Sayeed, I.; Parvez, S.; Winkler-Stuck, K.; Seitz, G.; Trieu, I.; Wallesch, C. W.; Schonfeld, P.; Siemen, D. Patch clamp reveals powerful blockade of the mitochondrial permeability transition pore by the D2-receptor agonist pramipexole. FASEB J. 2006, 20, 556-558.
23. Huang, F.; Vemuri, M. C.; Schneider, J. S. Modulation of ATP levels alters the mode of hydrogen peroxide-induced cell death in primary cortical cultures: effects of putative neuroprotective agents. Brain Res. 2004, 997, 79-88.
24. Ramirez, A. D.; Wong, S. K.; Menniti, F. S. Pramipexole inhibits MPTP toxicity in mice by dopamine D3 receptor dependent and independent mechanisms. Eur. J. Pharmacol. 2003, 475, 29-35.
25. Iravani M. M.; Haddon C. O.; Cooper J. M.; Jenner P.; Schapira A. H. Pramipexole protects against MPTP toxicity in non-human primates. J. Neurochem. 2006, 96, 1315-1321.
26. Iravani, M. M.; Sadeghian, M.; Leung, C. C.; Tel, B. C.; Rose, S.; Schapira, A. H.; Jenner, P. Continuous subcutaneous infusion of pramipexole protects against lipopolysaccharide-induced dopaminergic cell death without affecting the inflammatory response. Exp. Neurol. 2008, 212, 522-531.
27. Chen, S.; Zhang, X.; Yang, D.; Du, Y.; Li, L.; Li, X.; Ming, M.; Le, W. D2/D3 receptor agonist ropinirole protects dopaminergic cell line against rotenone-induced apoptosis through inhibition of caspase- and JNK-dependent pathways. FEBS Lett. 2008, 582, 603-610.
28. Nair, V. D.; Olanow, C. W. Differential modulation of Akt/glycogen synthase kinase-3beta pathway regulates apoptotic and cytoprotective signaling responses. J. Biol. Chem. 2008, 283, 15469-15478.
29. Tanaka, K.; Miyazaki, I.; Fujita, N.; Haque, M. E.; Asanuma, M.; Ogawa, N. Molecular mechanism in activation of glutathione system by ropinirole, a selective dopamine D2 agonist. Neurochem. Res. 2001, 26, 31-36.
30. Iida, M.; Miyazaki, I.; Tanaka, K.; Kabuto, H.; Iwata-Ichikawa, E.; Ogawa, N. Dopamine D2 receptor-mediated antioxidant and neuroprotective effects of ropinirole, a dopamine agonist. Brain Res. 1999, 838, 51-59.
31. Scheller, D.; Stichel-Gunkel, C.; Lubbert, H.; Porras, G.; Ravenscroft, P.; Hill, M.; Bezard, E. Neuroprotective effects of rotigotine in the acute MPTP-lesioned mouse model of Parkinson's disease. Neurosci. Lett. 2008, 432, 30-34.
32. Scheller, D.; Chan, P.; Li, Q.; Wu, T.; Zhang, R.; Guan, L.; Ravenscroft, P.; Guigoni, C.; Crossman, A. R.; Hill, M.; Bezard, E. Rotigotine treatment partially protects from MPTP toxicity in a progressive macaque model of Parkinson's disease. Exp. Neurol. 2007, 203, 415-422.
33. Zoccarato, F.; Cappellotto, M.; Alexandre, A. Clorgyline and other propargylamine derivatives as inhibitors of succinate-dependent H(2)O(2) release at NADH:UBIQUINONE oxidoreductase (Complex I) in brain mitochondria. J. Bioenerg. Biomembr. 2008, 40, 289-296.
34. Zhu, W.; Xie, W.; Pan, T.; Jankovic, J.; Li, J.; Youdim, M. B.; Le, W. Comparison of neuroprotective and neurorestorative capabilities of rasagiline and selegiline against lactacystin-induced nigrostriatal dopaminergic degeneration. J. Neurochem. 2008, 105, 1970-1978.
35. Weinreb, O.; Amit, T.; Bar-Am, O.; Youdim, M. B. Induction of neurotrophic factors GDNF and BDNF associated with the mechanism of neurorescue action of rasagiline and ladostigil: new insights and implications for therapy. Ann. N. Y. Acad. Sci. 2007, 1122, 155-168.
36. Schapira, A.; Bate, G.; Kirkpatrick, P. Rasagiline. Nat. Rev. Drug Discov. 2005, 4, 625-626.
37. Schapira A. H. The clinical relevance of levodopa toxicity in the treatment of Parkinson's disease. Mov. Disord. 2008, 23 (Suppl. 3), S515-520.
38. Schapira, A. H. Molecular and clinical pathways to neuroprotection of dopaminergic drugs in Parkinson disease. Neurology 2009, 72, S44-S50.
39. A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease. The Parkinson Study Group. Arch. Neurol. 2004, 61, 561-566.
40. Hauser, R. A.; Lew, M. F.; Hurtig, H. I.; Ondo, W. G.; Wojcieszek, J.; Fitzer-Attas, C. J. Long-term outcome of early versus delayed rasagiline treatment in early Parkinson's disease. Mov. Disord. 2009, 24, 564-573.
41. Nissinen, H.; Kuoppamäki, M.; Leinonen, M.; Schapira, A.H. Early versus delayed initiation of entacapone in levodopa-treated patients with Parkinson's disease: a long-term, retrospective analysis. Eur. J. Neurol. 2009, in press.
42. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. The Parkinson Study Group. N. Engl. J. Med. 1993, 328, 176-183.
43. Olanow, C. W.; Hauser, R. A.; Gauger, L.; Malapira, T.; Koller, W.; Hubble, J.; Bushenbark, K.; Lilienfeld, D.; Esterlitz, J. The effect of deprenyl and levodopa on the progression of Parkinson's disease. Ann. Neurol. 1995, 38, 771-777.
44. Larsen, J. P.; Boas, J.; Erdal, J. E. Does selegiline modify the progression of early Parkinson's disease? Results from a five-year study. The Norwegian-Danish Study Group. Eur. J. Neurol. 1999, 6, 539-547.
45. Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP subjects not requiring levodopa. Parkinson Study Group. Ann. Neurol. 1996, 39, 29-36.
46. Watts, R. L.; Jankovic, J.; Waters, C.; Rajput, A.; Boroojerdi, B.; Rao, J. Randomized, blind, controlled trial of transdermal rotigotine in early Parkinson disease. Neurology 2007, 68, 272-276.
47. Whone, A. L.; Watts, R. L.; Stoessl, A. J.; Davis, M.; Reske, S.; Nahmias, C.; Lang, A. E.; Rascol, O.; Ribeiro, M. J.; Remy, P.; Poewe, W. H.; Hauser, R. A.; Brooks, D. J. Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study. Ann. Neurol. 2003, 54, 93-101.
48. Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. Parkinson Study Group. JAMA 2002, 287, 1653-1661.
49. Schapira A. H.; Hsu H. H.; Scrine K.; Gordon M. F.; Marek K. L. PROUD: The impact of early vs. delayed treatment with pramipexole on new onset Parkinson's disease. Eur. J. Neurol. 2008, 15 (Suppl. 3), 132 (P1366).
50. Fahn, S. Does levodopa slow or hasten the rate of progression of Parkinson's disease? J. Neurol. 2005, 252 (Suppl. 4), IV37-IV42.
51. Schapira A. H.; Obeso J. Timing of treatment initiation in Parkinson's disease: a need for reappraisal? Ann. Neurol. 2006, 59, 559-562.
52. Rascol, O.; Brooks, D. J.; Korczyn, A. D.; De Deyn, P. P.; Clarke, C. E.; Lang, A. E.; Abdalla, M. Development of dyskinesias in a 5-year trial of ropinirole and L-dopa. Mov. Disord. 2006, 21, 1844-1850.
53. Hauser, R. A.; Rascol, O.; Korczyn, A. D.; Jon, S. A.; Watts, R. L.; Poewe, W.; De Deyn, P. P.; Lang, A. E. Ten-year follow-up of Parkinson's disease patients randomized to initial therapy with ropinirole or levodopa. Mov. Disord. 2007, 22, 2409-2417.
54. Pramipexole vs levodopa as initial treatment for Parkinson disease: A randomized controlled trial. Parkinson Study Group. JAMA 2000, 284, 1931-1938.
55. Holloway, R. G.; Shoulson, I.; Fahn, S.; Kieburtz, K.; Lang, A.; Marek, K.; McDermott, M.; Seibyl, J.; Weiner, W.; Musch, B.; Kamp, C.; Welsh, M.; Shinaman, A.; Pahwa, R.; Barclay, L.; Hubble, J.; LeWitt, P.; Miyasaki, J.; Suchowersky, O.; Stacy, M.; Russell, D. S.; Ford, B.; Hammerstad, J.; Riley, D.; Standaert, D.; Wooten, F.; Factor, S.; Jankovic, J.; Atassi, F.; Kurlan, R.; Panisset, M.; Rajput, A.; Rodnitzky, R.; Shults, C.; Petsinger, G.; Waters, C.; Pfeiffer, R.; Biglan, K.; Borchert, L.; Montgomery, A.; Sutherland, L.; Weeks, C.; DeAngelis, M.; Sime, E.; Wood, S.; Pantella, C.; Harrigan, M.; Fussell, B.; Dillon, S.; exander-Brown, B.; Rainey, P.; Tennis, M.; Rost-Ruffner, E.; Brown, D.; Evans, S.; Berry, D.; Hall, J.; Shirley, T.; Dobson, J.; Fontaine, D.; Pfeiffer, B.; Brocht, A.; Bennett, S.; Daigneault, S.; Hodgeman, K.; O'Connell, C.; Ross, T.; Richard, K.; Watts, A. Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial. Arch. Neurol. 2004, 61, 1044-1053.
56. Gallagher, D. A.; Schrag, A. Impact of newer pharmacological treatments on quality of life in patients with Parkinson's disease. CNS Drugs 2008, 22, 563-586.
57. Aiken, C. B. Pramipexole in psychiatry: a systematic review of the literature. J. Clin. Psychiatry 2007, 68, 1230-1236.
58. Barone, P.; Scarzella, L.; Marconi, R.; Antonini, A.; Morgante, L.; Bracco, F.; Zappia, M.; Musch, B. Pramipexole versus sertraline in the treatment of depression in Parkinson's disease: a national multicenter parallel-group randomized study. J. Neurol. 2006, 253, 601-607.
59. Barone P.; Poewe W.; Massey D.; Debieuvre C. Pramipexole ameliorates depression in Parkinson's disease: A randomized double-blind vs placebo trial. Abstract S43.004, presented during scientific session 'Evaluation and Treatment of Parkinson's Disease' on April 30, 2009 at AAN 61st Annual Meeting, Seattle, USA.
60. Schapira AH. Progress in neuroprotection in Parkinson's disease. Eur. J. Neurol. 2008, 15, (Suppl. 1), 5-13.
61. Shults, C. W.; Oakes, D.; Kieburtz, K.; Beal, M. F.; Haas, R.; Plumb, S.; Juncos, J. L.; Nutt, J.; Shoulson, I.; Carter, J.; Kompoliti, K.; Perlmutter, J. S.; Reich, S.; Stern, M.; Watts, R. L.; Kurlan, R.; Molho, E.; Harrison, M.; Lew, M. Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline. Arch. Neurol. 2002, 59, 1541-1550.
62. Muller, T.; Buttner, T.; Gholipour, A. F.; Kuhn, W. Coenzyme Q10 supplementation provides mild symptomatic benefit in patients with Parkinson's disease. Neurosci. Lett. 2003, 341, 201-204.
63. Storch, A.; Jost, W. H.; Vieregge, P.; Spiegel, J.; Greulich, W.; Durner, J.; Muller, T.; Kupsch, A.; Henningsen, H.; Oertel, W. H.; Fuchs, G.; Kuhn, W.; Niklowitz, P.; Koch, R.; Herting, B.; Reichmann, H. Randomized, double-blind, placebo-controlled trial on symptomatic effects of coenzyme Q(10) in Parkinson disease. Arch. Neurol. 2007, 64, 938-944.
64. A pilot clinical trial of creatine and minocycline in early Parkinson disease: 18-month results. NINDS NET-PD Investigators. Clin. Neuropharmacol. 2008, 31, 141-150.
65. Bloom, M. Z. NIH announces phase III clinical trial of creatine for Parkinson's disease. Consult. Pharm. 2007, 22, 378.
66. Bender, A.; Koch, W.; Elstner, M.; Schombacher, Y.; Bender, J.; Moeschl, M.; Gekeler, F.; Muller-Myhsok, B.; Gasser, T.; Tatsch, K.; Klopstock, T. Creatine supplementation in Parkinson disease: a placebo-controlled randomized pilot trial. Neurology 2006, 67, 1262-1264.
67. Shoulson, I. DATATOP: a decade of neuroprotective inquiry. Parkinson Study Group. Deprenyl and tocopherol antioxidative therapy of parkinsonism. Ann. Neurol. 1998, 44 (3 Suppl. 1), S160-S166.
68. Etminan, M.; Gill, S. S.; Samii, A. Intake of vitamin E, vitamin C, and carotenoids and the risk of Parkinson's disease: a meta-analysis. Lancet Neurol. 2005, 4, 362-365.
69. Jankovic, J.; Hunter, C. A double-blind, placebo-controlled and longitudinal study of riluzole in early Parkinson's disease. Parkinsonism Relat. Disord. 2002, 8, 271-276.
70. Rodnitzky, R. L. Can calcium antagonists provide a neuroprotective effect in Parkinson's disease? Drugs 1999, 57, 845-849.
71. Becker, C.; Jick, S. S.; Meier, C. R. Use of antihypertensives and the risk of Parkinson disease. Neurology 2008, 70, 1438-1444.
72. Ton, T. G.; Heckbert, S. R.; Longstreth, W. T., Jr.; Rossing, M. A.; Kukull, W. A.; Franklin, G. M.; Swanson, P. D.; Smith-Weller, T.; Checkoway, H. Calcium channel blockers and beta-blockers in relation to Parkinson's disease. Parkinsonism Relat. Disord. 2007, 13, 165-169.
73. Olanow, C. W.; Schapira, A. H.; LeWitt, P. A.; Kieburtz, K.; Sauer, D.; Olivieri, G.; Pohlmann, H.; Hubble, J. TCH346 as a neuroprotective drug in Parkinson's disease: a double-blind, randomised, controlled trial. Lancet Neurol. 2006, 5, 1013-1020.
74. Schapira, A. H.; Emre, M.; Jenner, P.; Poewe, W. Levodopa in the treatment of Parkinson's disease. Eur. J. Neurol. 2009, in press.
75. Bet, L.; Bareggi, S. R.; Pacei, F.; Bondiolotti, G.; Meola, G.; Schapira, A.H. Bimodal administration of entacapone in Parkinson's disease patients improves motor control. Eur. J. Neurol. 2008, 15, 268-273.
76. Pahwa, R.; Factor, S. A.; Lyons, K. E.; Ondo, W. G.; Gronseth, G.; Bronte-Stewart, H.; Hallett, M.; Miyasaki, J.; Stevens, J.; Weiner, W. J. Practice Parameter: treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2006, 66, 983-995.
77. A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Parkinson Study Group. Arch. Neurol. 2005, 62, 241-248.
78. Rascol, O.; Brooks, D. J.; Melamed, E.; Oertel, W.; Poewe, W.; Stocchi, F.; Tolosa, E. Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial. Lancet 2005, 365, 947-954.
79. Entacapone improves motor fluctuations in levodopa-treated Parkinson's disease patients. Parkinson Study Group. Ann. Neurol. 1997, 42, 747-755.
80. Poewe, W. H.; Rascol, O.; Quinn, N.; Tolosa, E.; Oertel, W. H.; Martignoni, E.; Rupp, M.; Boroojerdi, B. Efficacy of pramipexole and transdermal rotigotine in advanced Parkinson's disease: a double-blind, double-dummy, randomised controlled trial. Lancet Neurol. 2007, 6, 513-520.
81. Kurth, M. C.; Tetrud, J. W.; Tanner, C. M.; Irwin, I.; Stebbins, G. T.; Goetz, C. G.; Langston, J. W. Double-blind, placebo-controlled, crossover study of duodenal infusion of levodopa/carbidopa in Parkinson's disease patients with 'on-off' fluctuations. Neurology 1993, 43, 1698-1703.
82. Snow, B. J.; Macdonald, L.; Mcauley, D.; Wallis, W. The effect of amantadine on levodopa-induced dyskinesias in Parkinson's disease: a double-blind, placebo-controlled study. Clin. Neuropharmacol. 2000, 23, 82-85.
83. Schapira, A.H. Treatment options in the modern management of Parkinson disease. Arch. Neurol. 2007, 64, 1083-1088.
84. Schapira, A.H.; Olanow, C.W. Drug selection and timing of initiation of treatment in early Parkinson's disease. Ann. Neurol. 2008, 64, (Suppl. 2), S47-55.
85. Schapira, A.H. Etiology of Parkinson's disease. Neurology. 2006, 66, S10-23.
86. Schapira, A. H. Neurobiology and Treatment of Parkinson's Disease. Trends Pharmacol. Sci. 2009, 30, 41-47.